Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.03 per share a year ago.
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Xeris Biopharma (XERS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call.
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
